Tanezumab
Tanezumab is an antibody pharmaceutical. It is currently being investigated in clinical studies. The pharmaceutical is active against beta-nerve growth factor.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
40 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Osteoarthritis | D010003 | EFO_0002506 | M15-M19 | — | 2 | 14 | — | — | 16 |
| Low back pain | D017116 | HP_0003419 | M54.5 | 1 | 3 | 3 | — | — | 7 |
| Arthritis | D001168 | HP_0001369 | M05-M14 | — | 1 | 5 | — | — | 6 |
| Knee osteoarthritis | D020370 | EFO_0004616 | M17 | — | 2 | 3 | — | — | 5 |
| Hip osteoarthritis | D015207 | EFO_1000786 | M16 | — | 1 | 4 | — | — | 5 |
| Cancer pain | D000072716 | — | G89.3 | — | — | 2 | — | — | 2 |
| Pain | D010146 | EFO_0003843 | R52 | — | 1 | 1 | — | — | 2 |
| Neoplasm metastasis | D009362 | EFO_0009708 | — | — | 1 | 1 | — | — | 2 |
| Chronic pain | D059350 | HP_0012532 | — | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Interstitial cystitis | D018856 | EFO_1000869 | N30.1 | 1 | 2 | — | — | — | 3 |
| Diabetic neuropathies | D003929 | EFO_1000783 | — | — | 1 | — | — | — | 1 |
| Neurilemmoma | D009442 | EFO_0000693 | — | — | 1 | — | — | — | 1 |
| Chronic pancreatitis | D050500 | EFO_0000342 | K86.1 | — | 1 | — | — | — | 1 |
| Neoplasms | D009369 | — | C80 | — | 1 | — | — | — | 1 |
| Prostatitis | D011472 | EFO_0003830 | N41 | — | 1 | — | — | — | 1 |
| Endometriosis | D004715 | EFO_0001065 | N80 | — | 1 | — | — | — | 1 |
| Postherpetic neuralgia | D051474 | — | — | — | 1 | — | — | — | 1 |
| Palliative care | D010166 | — | — | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Spine osteoarthritis | D055013 | EFO_1000787 | — | 1 | — | — | — | — | 1 |
| Healthy volunteers/patients | — | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Tanezumab |
| INN | tanezumab |
| Description | Tanezumab (humanized mab) |
| Classification | Antibody |
| Drug class | monoclonal antibodies |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | >4EDW:H|tanezumab Fab heavy chain
QVQLQESGPGLVKPSETLSLTCTVSGFSLIGYDLNWIRQPPGKGLEWIGIIWGDGTTDYNSAVKSRVTISKDTSKNQFSL
KLSSVTAADTAVYYCARGGYWYATSYYFDYWGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTV
SWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSNFGTQTYTCNVDHKPSNTKVDKTVERKTSHHHHHHG
>4EDW:L|tanezumab Fab light chain
DIQMTQSPSSLSASVGDRVTITCRASQSISNNLNWYQQKPGKAPKLLIYYTSRFHSGVPSRFSGSGSGTDFTFTISSLQP
EDIATYYCQQEHTLPYTFGQGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQ
ESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC |
Identifiers
| PDB | 4EDW |
| CAS-ID | — |
| RxCUI | — |
| ChEMBL ID | CHEMBL2108567 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB12335 |
| UNII ID | EQL0E9GCX1 (ChemIDplus, GSRS) |
Target
Agency Approved
NGF
NGF
Alternate
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 761 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
89 adverse events reported
View more details
© 2020-2023 Collaborative Drug Discovery Inc. (CDD) | Terms of Use